Twenty four-week peginterferon plus ribavirin after interferon-&beta; induction for genotype 1b chronic hepatitis C

doi:10.4254/wjh.v2.i6.226

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 6

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4266)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

286

HTML

3347

Figures (1-3)

305

Tables (1-4)

328

Sum=4266

Jun 27, 2010 (publication date) through Mar 2, 2025

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Articles

World J Hepatol. Jun 27, 2010; 2(6): 226-232
Published online Jun 27, 2010. doi: 10.4254/wjh.v2.i6.226

Table 1 Clinical background of patients

	Background
n of patients	71
Male [n (%)]	31 (44)
Age (yr)	63 (32-78)
Body weight > 60 kg [n (%)]	33 (46)
HCV-RNA (Log IU/mL)	6.1 (5.1-7.2)
Alanine aminotransferase (U/L)	97 (27-513)
Platelet count [× 10⁴/μL]	13.9 (9.1-30.6)
9.0 to 13.0 [n (% )]	28 (39)
≥ 13.0 [n (% )]	43 (61)
Albumin (g/dL)	3.9 (3.5-4.5)
Hemoglobin (g/dL)	13.6 (10.5-16.9)
Interferon-naïve [n (%)]	44 (62)
Peginterferon-α2a/-α2b (n)	34/37
Initial dose of ribavirin	38/30/3
600/800/1 000 (mg/d) (n)

Continuous variables: Median (range).

Table 2 Clinical background by therapeutic response

	Dosing duration of peginterferon plus ribavirin
	1-24 wk		20-24 wk
	SVR non-SVR	P value	SVR non-SVR	P value
n of patients	21		17
n of patients	40		14
Male [n (%)]	12 (57)	0.0636^b	10 (59)	0.1493^c
Male [n (%)]	13 (33)	0.0636^b	4 (29)	0.1493^c
Age (yr)	58 (35-74)	0.0030^a	58 (35-74)	0.0134^a
Age (yr)	65 (37-78)	0.0030^a	63 (58-71)	0.0134^a
Body weight > 60 kg [n (%)]	13 (62)	0.0441^b	10 (59)	0.0669^c
Body weight > 60 kg [n (%)]	14 (35)	0.0441^b	3 (21)	0.0669^c
HCV-RNA (Log IU/mL)	5.8 (5.1-6.9)	0.1685^a	6.0 (5.2-6.9)	0.9967^a
HCV-RNA (Log IU/mL)	6.1 (5.1-7.2)	0.1685^a	6.1 (5.2-6.6)	0.9967^a
Alanine amino-transferase (U/L)	97 (52-269)	0.7699^a	86 (57-138)	0.6410^a
Alanine amino-transferase (U/L)	93 (27-513)	0.7699^a	80 (28-260)	0.6410^a
Platelet count (× 10⁴/μL)	16.8 (10.9-30.6)	0.0020^a	17.0 (10.9-30.6)	0.0007^a
Platelet count (× 10⁴/μL)	13.3 (9.1-24.0)	0.0020^a	11.4 (9.1-15.4)	0.0007^a
Albumin (g/dL)	3.9 (3.5-4.4)	0.7410^a	3.9 (3.5-4.2)	0.9211^a
Albumin (g/dL)	3.9 (3.5-4.5)	0.7410^a	3.9 (3.5-4.5)	0.9211^a
Hemoglobin (g/dL)	14.4 (11.4-15.4)	0.0126^a	14.5 (11.4-15.4)	0.1379^a
Hemoglobin (g/dL)	13.1 (10.5-15.4)	0.0126^a	13.5 (10.7-15.4)	0.1379^a
Interferon-naïve [n (%)]	12 (57)	0.6847^b	9 (53)	0.8150^b
Interferon-naïve [n (%)]	25 (63)	0.6847^b	8 (57)	0.8150^b
Peginterferon-α2a/-α2b (n)	12/9	0.2016^b	9/8	0.4607^c
Peginterferon-α2a/-α2b (n)	16/24	0.2016^b	10/4	0.4607^c
Dosing duration of peginterferon (wk)	24 (4-24)	0.0009^a	24 (21-24)	0.5082^a
Dosing duration of peginterferon (wk)	15 (2-24)	0.0009^a	24 (21-24)	0.5082^a

Continuous variables: Median (range); Statistical analysis:

^aAnalysis of variance;

^bχ² test;

^cFisher’s exact test; SVR: Sustained virologic response.

Table 3 Nominal logistic regression analysis of clinical background variables related to an sustained virologic response (SVR)

Variable	Odds ratio (95% CI)	P value¹
Dosing duration of peginterferon: 1-24 wk (n = 61)
Age < 65 yr	1.3210 (0.2140-8.1481)	0.7586
Body weight > 60 kg	3.7283 (0.6986-25.865)	0.1257
Platelet count ≥ 130 000/μL	15.301 (2.5378-155.22)	0.0018
Hemoglobin ≥ 14.0 g/dL	4.7957 (0.9337-30.599)	0.0606
Dosing duration of Peg-IFN 20-24 wk (vs 1-19 wk)	33.551 (5.5858-352.77)	< 0.0001
Dosing duration of peginterferon: 20-24 wk (n = 31)
Age < 65 yr	1.1028 (0.1670-6.6558)	0.9149
Platelet count ≥ 130 000/μL	11.680 (2.3064-79.474)	0.0024

CI: Confidence interval;

¹Statistical analysis: Likelihood ratio test.

Table 4 HCV-RNA response during treatment and outcome

Response outcome	IFN-β¹n (%)¹	HCV-RNA¹	RVR n (%)	cEVR n (%)	ETR n (%)
Dosing duration of peginterferon: 1-24 wk (n = 61)
Yes	43 (70)	6.0 (5.1-7.1)^b	15 (25)	36 (59)	39 (64)
SVR	21 (49)^a	5.8 (5.1-6.9)	7 (47)	20 (56)^c	21 (54)^d
Non-SVR	22 (51)^a	6.0 (5.1-7.1)	8 (53)	16 (44)^c	18 (46)^d
No	18 (30)	6.2 (5.5-7.2)^b	46 (75)	25 (41)	22 (36)
SVR	0 (0)^a	-	14 (30)	1 (4)^c	0 (0)^d
Non-SVR	18 (100)^a	6.2 (5.5-7.2)	32 (70)	24 (96)^c	22 (100)^d
Dosing duration of peginterferon: 20-24 wk (n = 31)
Yes	25 (81)	6.0 (5.2-6.9)	11 (35)	24 (77)	24 (77)
SVR	17 (68)^e	6.0 (5.2-6.9)	7 (64)	17 (71)^f	17 (71)^g
Non-SVR	8 (32)^e	5.7 (5.2-6.6)	4 (36)	7 (29)^f	7 (29)^g
No	6 (19)	6.4 (5.5-6.6)	20 (65)	7 (23)	7 (23)
SVR	0 (0)^e	-	10 (50)	0 (0)^f	0 (0)^g
Non-SVR	6 (100)^e	6.4 (5.5-6.6)	10 (50)	7 (100)^f	7 (100)^g

¹Number (%) of patients that HCV-RNA decreased to below 3.3 Log IU/mL or turned negative at the end of IFN-β treatment, and median (range) of the HCV-RNA (Log IU/mL) before treatment among those patients. RVR: Rapid virologic response; cEVR: Complete early virologic response; ETR: End-of-treatment response.

^aP < 0.0001;

^bP < 0.05;

^cP < 0.001;

^dP< 0.0001;

^eP < 0.01;

^fP < 0.01;

^gP < 0.01; Statistical analysis:^{a, c, d, e, f, g}; Fisher’s exact test:^b; Analysis of variance.

Citation: Okushin H, Morii K, Uesaka K, Yuasa S. Twenty four-week peginterferon plus ribavirin after interferon-β induction for genotype 1b chronic hepatitis C. World J Hepatol 2010; 2(6): 226-232
URL: https://www.wjgnet.com/1948-5182/full/v2/i6/226.htm
DOI: https://dx.doi.org/10.4254/wjh.v2.i6.226